Inhibitory Effect of Silibinin on Variation of Leptin Gene Expression in the T47D Breast Cancer Cell Line
Objective: Leptin, a 16 kDa adipocytokine, has many roles in the body. Recently, it has been showed that leptin could be involved in the breast carcinogenesis as a mitogenic factor. Therefore, it could be considered as a target for breast cancer therapy. The expression of leptin is affected from estrogen receptors. Silibinin, a flavonolignan of sylibium marinum, is an herbal agent with anti-cancer activity on prostate and colorectal cancers. The aim of this study was investigation of silibinin effect on leptin gene expression.
Materials and Methods: For this purpose, T47D breast cancer cells treated with 20, 40, 60 and 100μM concentrations of silibinin for 24h. Then, expression of leptin in the control and test groups was measured by real-time PCR.
Results: Analysis of data showed significant decrease in leptin expression with increase in silibinin concentration (p<0.05). Based on the previous studies, silibinin could increase expression of estrogen receptor β with no effect on estrogen receptor α. Therefore, we propose that decrease in the leptin expression by silibinin may be through estrogen receptor beta.
Conclusion: Based on our results, silibinin could be used as drug candidate for the breast cancer therapy through the leptin targeting.